Cart
sales@molnova.com
N,N,O-Tridesmethylvenlafaxine
CAS No. 149289-29-2
N,N,O-Tridesmethylvenlafaxine( Tridesmethylvenlafaxine )
Catalog No. M28629 CAS No. 149289-29-2
N,N,O-Tridesmethylvenlafaxine is an endogenous metabolite.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 178 | Get Quote |
|
| 10MG | 267 | Get Quote |
|
| 25MG | 464 | Get Quote |
|
| 50MG | 662 | Get Quote |
|
| 100MG | 888 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameN,N,O-Tridesmethylvenlafaxine
-
NoteResearch use only, not for human use.
-
Brief DescriptionN,N,O-Tridesmethylvenlafaxine is an endogenous metabolite.
-
DescriptionN,N,O-Tridesmethylvenlafaxine is an endogenous metabolite.
-
In Vitro——
-
In Vivo——
-
SynonymsTridesmethylvenlafaxine
-
PathwayOthers
-
TargetOther Targets
-
RecptorROCK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number149289-29-2
-
Formula Weight235.32
-
Molecular FormulaC14H21NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNCC(C1(CCCCC1)O)c(cc1)ccc1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tokushige H, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3216-22.
molnova catalog
related products
-
Super-TDU (1-31) TFA
Super-tdu (1-31) TFA is an endogenous ligand of heptapeptide receptor and has a strong anti-analgesic effect.
-
Daurichromenic acid
Daurichromenic acid is a chromene, which can be isolated from the leaves and twigs of Rhododendron dauricum. Daurichromenic acid has potent anti-HIV activity with an EC50 value of 0.00567 μg/mL.
-
Amylin (20-29) (huma...
Amylin (20-29) (human) is the fragment of human islet amyloid polypeptide (hIAPP) or Amylin. Amylin is a 37-residue hormone. Amylin (20-29) (human) is responsible for the amyloidogenic propensities of the full length protein. Amylin (20-29) (human) can be transformed into its corresponding peptoid and retropeptoid sequences, to obtain beta-sheet breaker peptides as amyloid inhibitors.
